Benzinga | Nov 9, 2021 11:46AM EST

New Analysis To Be Presented At The American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021.

The new analysis will be presented by Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital, professor of medicine at Harvard Medical School, and study chair for the SOLOIST and SCORED trials. The presentation is entitled, "Cardiovascular Benefits of Sodium Glucose Cotransporter-1/2 Inhibition with Sotagliflozin Across Baseline Kidney Function."

The presentation will be broadcast live at 8:24 a.m. Eastern on Sunday, November 14 during the main featured science session entitled, "Cardiometabolic Disease and Heart Failure: Digging Deeper and Treating Earlier" and the abstract will be posted on the AHA website at that time.